2025
SJR Q2
JCR Q2 · 3,6
OA
8 matched articles
SCIE
Journal detail
Journal of Bone Oncology
- Publisher
- Elsevier GmbH
- Country
- Germany · Western Europe
- Type
- journal
- ISSN
-
22121374
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,087
- Quartile Q2
- H-Index 46
- Cites/doc 3,94
- Docs (3y) 172
- Cites (3y) 712
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,6
- 5Y JIF 3,7
- JCI 0,73
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Oncology Q2
Areas
- Medicine
WoS categories
- Oncology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 1,087 | 3,6 | 3,7 | 0,73 | Q2 | 46 |
| 2024 | Q2 | Q2 | 1,041 | 3,5 | 3,6 | 0,7 | Q2 | 41 |
| 2023 | Q2 | Q2 | 0,806 | 3,1 | 3,2 | 0,69 | Q2 | 41 |
| 2022 | Q2 | Q3 | 0,92 | 3,4 | 3,8 | 0,71 | Q2 | 41 |
| 2021 | Q2 | Q2 | 0,778 | 4,5 | 4,3 | 0,68 | Q2 | 41 |
| 2020 | Q2 | Q3 | 1,015 | 4,1 | 4,2 | 0,69 | Q3 | 41 |
| 2019 | Q2 | Q3 | 0,95 | 3,1 | 3,1 | 0,7 | Q2 | 41 |
| 2018 | — | Q3 | — | 2,9 | 2,8 | 0,65 | Q3 | — |
| 2017 | Q2 | Q2 | 0,941 | 3,5 | 2,5 | 0,66 | Q3 | 41 |
| 2016 | Q3 | Q4 | 0,42 | 1,5 | 1,3 | — | — | 41 |
| 2015 | Q3 | Q4 | 0,432 | 0,9 | 0,8 | — | — | 41 |
| 2014 | Q3 | Q4 | 0,556 | 1,2 | 1,2 | — | — | 41 |
| 2013 | Q3 | — | 0,216 | — | — | — | — | 41 |
| 2012 | — | — | — | — | — | — | — | 41 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q2 | Q2 | 132/333 |
| 2024 | ONCOLOGY | SCIE | Q2 | Q2 | 106/328 |
| 2023 | ONCOLOGY | SCIE | Q2 | Q2 | 136/322 |
| 2022 | ONCOLOGY | SCIE | Q3 | Q2 | 125/241 |
| 2021 | ONCOLOGY | SCIE | Q2 | Q2 | 114/245 |
| 2020 | ONCOLOGY | SCIE | Q3 | Q3 | 126/242 |
| 2019 | ONCOLOGY | SCIE | Q3 | Q2 | 135/244 |
| 2018 | ONCOLOGY | SCIE | Q3 | Q3 | 126/230 |
| 2017 | ONCOLOGY | SCIE | Q2 | Q3 | 93/223 |
| 2016 | ONCOLOGY | SCIE | Q4 | — | 187/217 |
| 2015 | ONCOLOGY | SCIE | Q4 | — | 201/213 |
| 2014 | ONCOLOGY | SCIE | Q4 | — | 187/211 |